clinical trial · NCT03559660
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
UCB Biopharma SRL·—·no longer available
Crohn's DiseaseCertolizumab Pegol
brief summary
The objective of this program is to allow treating physicians to supply/continue to supply Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are considered not suitable for treatment, intolerant, have medical contraindications or had insufficient response with an authorized conventional therapy, including other authorized biologics.
started
—
primary completion
—
completion
—
last updated
Jun 11, 2025
official title
Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol